Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia

International Journal of Clinical Pharmacy

Volumn 35, Issue 5, 2013, Pages 711-718

  Lee, Eun Kyung ^b   Lee, Yu Jeung ^a  

^a Kangwon National University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

Anticholinergic agents; Dementia; Elderly; Side effects; South Korea

Indexed keywords

AMANTADINE; BACLOFEN; CARBIDOPA PLUS LEVODOPA; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLOZAPINE; CYCLOBENZAPRINE; CYPROHEPTADINE; DESIPRAMINE; ENTACAPONE; HALOPERIDOL; LOPERAMIDE; LORATADINE; METOCLOPRAMIDE; MIRTAZAPINE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PRAMIPEXOLE; PROCHLORPERAZINE; PSEUDOEPHEDRINE; QUETIAPINE; RANITIDINE; RISPERIDONE; SELEGILINE; TOLTERODINE; TRAZODONE; UNINDEXED DRUG; ZIPRASIDONE;

AGED; ANTICHOLINERGIC SYNDROME; ARTICLE; ASIAN; COMORBIDITY; DEMENTIA; FACTORIAL ANALYSIS; FEMALE; HUMAN; KOREAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTPATIENT; OUTPATIENT CARE; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; SOUTH KOREA; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CHOLINERGIC ANTAGONISTS; COMORBIDITY; DEMENTIA; ELECTRONIC HEALTH RECORDS; FEMALE; GERIATRIC ASSESSMENT; HEALTH SERVICES FOR THE AGED; HOSPITALS, UNIVERSITY; HUMANS; MALE; MOOD DISORDERS; NORTRIPTYLINE; OUTPATIENT CLINICS, HOSPITAL; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES;

EID: 84886096338     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-013-9793-9     Document Type: Article

References (27)

1. Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther. 2012;134:8-25.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
3. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-97.
4. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210-6.
5. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess. 2006;10:1-160.
6. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-8.
7. Schneider LS. AD2000: donepezil in Alzheimer's disease. Lancet. 2004;363:2100-1.
8. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616-31.
9. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55:S373-82.
10. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477-83.
11. Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225-33.
12. Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311-20.
13. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481-6.
14. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508-13.
15. Bhattacharya R, Chatterjee S, Carnahan RM, Aparasu RR. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am J Geriatr Pharmacother. 2011;9:434-41.
16. Chatterjee S, Mehta S, Sherer JT, Aparasu RR. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey. Drugs Aging. 2010;27:987-97.
17. Low LF, Anstey KJ, Sachdev P. Use of medications with anticholinergic properties and cognitive function in a young-old community sample. Int J Geriatr Psychiatry. 2009;24:578-84.
18. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60:198-203.
19. Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry. 2005;13:535-8.
20. Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Re′glat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol. 2005;59:143-51.
21. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002;50:836-42.
22. Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161:1099-105.
23. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481-6.
24. Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale: results from the REPOSI study. Drugs Aging. 2013;30:103-12.
25. Karimi S, Dharia SP, Flora DS, Slattum PW. Anticholinergic burden: clinical implications for seniors and strategies for clinicians. Consult Pharm. 2012;27:564-82.
26. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55:809-17.
27. Lau DT, Kasper JD, Potter DE, Lyles A. Potentially inappropriate medication prescriptions among elderly nursing home residents: their scope and associated resident and facility characteristics. Health Serv Res. 2004;39:1257-76.